MedTrace Logo

Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study

NCT03640884 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30000

Last updated 2021-07-07

No results posted yet for this study

Summary

This registry aims to monitor the safety of Xueshuantong Injection and to identify the potential risk factors for the adverse drug reactions.

Conditions

  • Adverse Drug Event
  • Adverse Drug Reactions
  • Anaphylactic Reaction
  • Severe Adverse Reactions

Interventions

DRUG

Xueshuantong-Injection

Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.

Sponsors & Collaborators

  • Zhong Wang

    lead OTHER

Principal Investigators

  • Zhong Wang, M.D. · Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

  • Jinmin Liu, M.D. · Dongfang Hospital Affiliated to Beijing University of traditional Chinese medicine

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-18
Primary Completion
2021-12-31
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03640884 on ClinicalTrials.gov